Revance Therapeutics Inc (NASDAQ: RVNC) is -40.96% lower on its value in year-to-date trading and has touched a low of $2.30 and a high of $11.49 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RVNC stock was last observed hovering at around $5.20 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $5.19, the stock is -13.11% and -5.34% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing -0.19% at the moment leaves the stock 4.62% off its SMA200. RVNC registered -53.66% loss for a year compared to 6-month gain of 14.07%. The firm has a 50-day simple moving average (SMA 50) of $5.4997 and a 200-day simple moving average (SMA200) of $4.94435.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.24% loss in the last 1 month and extending the period to 3 months gives it a 93.66%, and is -2.08% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.64% over the week and 4.03% over the month.
Revance Therapeutics Inc (RVNC) has around 597 employees, a market worth around $540.69M and $243.90M in sales. Profit margin for the company is -117.88%. Distance from 52-week low is 125.65% and -54.83% from its 52-week high. The company has generated returns on investments over the last 12 months (-87.05%).
Revance Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.38 with sales reaching $68.2M over the same period.The EPS is expected to grow by 47.73% this year, but quarterly earnings will post 18.00% year-over-year. Quarterly sales are estimated to grow 20.10% in year-over-year returns.
238.0 institutions hold shares in Revance Therapeutics Inc (RVNC), with institutional investors hold 87.75% of the company’s shares. The shares outstanding are 104.18M, and float is at 95.08M with Short Float at 8.03%. Institutions hold 80.22% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 13.94 million shares valued at $35.82 million. The investor’s holdings represent 15.164 of the RVNC Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 8.57 million shares valued at $22.01 million to account for 9.3183 of the shares outstanding. The other top investors are FRANKLIN RESOURCES INC which holds 6.26 million shares representing 6.8092 and valued at over $16.09 million, while VANGUARD GROUP INC holds 6.5215 of the shares totaling 5.99 million with a market value of $15.41 million.
Revance Therapeutics Inc (RVNC) Insider Activity
The most recent transaction is an insider sale by Jordan Erica, the company’s Chief Commercial Officer. SEC filings show that Jordan Erica sold 2,392 shares of the company’s common stock on Apr 16 ’24 at a price of $3.80 per share for a total of $9096.0. Following the sale, the insider now owns 0.11 million shares.
Revance Therapeutics Inc disclosed in a document filed with the SEC on Mar 18 ’24 that Sjuts Dustin S (President) sold a total of 9,211 shares of the company’s common stock. The trade occurred on Mar 18 ’24 and was made at $5.04 per share for $46446.0. Following the transaction, the insider now directly holds 0.17 million shares of the RVNC stock.
Still, SEC filings show that on Mar 18 ’24, Moxie Dwight (CLO & GC) disposed off 8,125 shares at an average price of $5.04 for $40971.0. The insider now directly holds 137,815 shares of Revance Therapeutics Inc (RVNC).
